regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
=== von Reumont et al. (2012) === In a 2012 molecular study, von Reumont et al. challenge the monophyly of Vericrustacea: they present four versions of Pancrustacea cladogram (figures 1–4), and in all four figures Remipedia is a sister group to Hexapoda, and Branchiopoda is a sister group to (Remipedia + Hexapoda). Thus, their data strongly suggest that Branchiopoda is more closely related to Hexapoda and Remipedia than to Multicrustacea. Based on these data, they propose the following scenario of evolution of Branchiopoda, Remipedia and Hexapoda: under the impact of predatory fishes their common ancestors go to the littoral zone, then ancestors of Branchiopoda go to the ephemeral freshwater habitat, whereas ancestors of Remipedia go to the anchialine cave, and ancestors of Hexapoda go to the land.
Another less insidious tactic journals employ is to publish a large portion of its papers, or at least the papers expected to be highly cited, early in the calendar year. This gives those papers more time to gather citations. Several methods, not necessarily with nefarious intent, exist for a journal to cite articles in the same journal which will increase the journal's impact factor. Beyond editorial policies that may skew the impact factor, journals can take overt steps to game the system. For example, in 2007, the specialist journal Folia Phoniatrica et Logopaedica, with an impact factor of 0.66, published an editorial that cited all its articles from 2005 to 2006 in a protest against the "absurd scientific situation in some countries" related to use of the impact factor. The large number of citations meant that the impact factor for that journal increased to 1.44. As a result of the increase, the journal was not included in the 2008 and 2009 Journal Citation Reports. Coercive citation is a practice in which an editor forces an author to add extraneous citations to an article before the journal will agree to publish it, in order to inflate the journal's impact factor. A survey published in 2012 indicates that coercive citation has been experienced by one in five researchers working in economics, sociology, psychology, and multiple business disciplines, and it is more common in business and in journals with a lower impact factor. Editors of leading business journals banded together to disavow the practice.
The increase in the fraction of estradiol bound to SHBG results in a significant decrease in the percentage of free or unbound and hence bioactive estradiol. As a result, the bioavailability and potency of oral estradiol may be diminished relative to parenteral estradiol routes by some amount. However, a study found that the free fraction of estradiol was similar with doses of oral and topical estradiol that resulted in equivalent total estradiol levels.
The wide-spread interest in the very remarkable specimen of the giant squid, now lying on the beach a few miles below the city, is mainly due to its enormous size. It is believed to be the largest specimen ever found. Its great size and immense weight have thus far prevented its being moved for a more careful examination. A dozen men with blocks and tackle not being able even to turn it over. Another effort will be made with more extensive apparatus by which it is hoped to drag it from the pit in which it now lies and placing it higher up on the beach so that a careful and thorough examination in the interest of science can be made and the exact species determined. Professor Verrill of Yale and Profs. True and Dale [Dall] of the Smithsonian are in constant correspondence with Dr. DeWitt Webb, President of the St. Augustine Scientific, Literary and Historical Society, in regard to it. Several photographs have been taken of it, but owing to its position, these have not been satisfactory. Mrs. John L. Wilson believes it to belong to an extinct species. Its hide is three and a half inches thick and its head is covered by a hood that prevents examination. Apparently it is a mass of cartilage and may have been dead in the water many days before it washed ashore on Anastasia Island. In the February issue of the American Journal of Science, Verrill even gave the animal a scientific name, Octopus giganteus (Verrill, 1897). He also added:
Sources: en.wikipedia.org
He also played a significant role in the winning elimination final against Western Bulldogs, but an injury sustained in the game ended his season. It was announced in early March 2021 that Ryder would temporarily step away from the club to spend time with his family and elders. Ryder received the full support of the club. Ryder returned to the club in April and played his first game for the season in the round seven win over Hawthorn in which he gathered five tackles, three clearances and 36 hitouts (significantly above the AFL average). Ryder had a purple patch in rounds 10-12, collecting 41, 34 and 34 hitouts in three games. Ryder also had a solid game in round 16 against Collingwood and champion Brodie Grundy, collecting 23 hitouts and kicking two goals. Ryder's last game for 2021 was Round 19, after which he battled an achilles injury which saw him miss the remainder of the season. After playing 12 of a possible 22 games and averaging over 30 hitouts a game, Ryder re-signed with the Saints for another season. After another injury-interrupted year for St Kilda during the side's 2022 season, Ryder announced his retirement on 20 August, ending a career of 281 games across three clubs.
=== Guatemala === The Mexican Army crackdown has driven some cartels to seek a safer location for their operations across the border in Guatemala, attracted by corruption, weak policing, and its position on the overland smuggling route. The smugglers pick up drugs from small planes that land at private airstrips hidden in the Guatemalan jungle. The cargo is then moved up through Mexico to the U.S. border. Guatemala has also arrested dozens of drug suspects and torched huge cannabis and poppy fields. The U.S. government sent speedboats and night-vision goggles under a regional drug aid package. Los Zetas have gained ground in Guatemala after they killed several high-profile members and the supreme leader of Los Leones, an organized crime group from Guatemala. In February 2009, Los Zetas threatened to kill the president of Guatemala, Álvaro Colom. On March 1, 2010, Guatemala's chief of national police and the country's top anti-drugs official were arrested over alleged links to drug trafficking. A report from the Brookings Institution warns that, without proactive, timely efforts, the violence will spread throughout the Central American region. In August 2025, Guatemala granted temporary humanitarian status to 161 Mexicans fleeing cartel violence in Chiapas.
== T == TI – Thermal ionization TIC - Total ion chromatogram TICC – Total ion current chromatogram, synonymous with TIC TLF – Time-lag focusing TMT – Tandem mass tags TOF-MS – Time-of-flight mass spectrometer
Liquefied gases, such as liquid nitrogen and liquid helium, are used in many cryogenic applications. Liquid nitrogen is the most commonly used element in cryogenics and is legally purchasable around the world. Liquid helium is also commonly used and allows for the lowest attainable temperatures to be reached. These liquids may be stored in Dewar flasks, which are double-walled containers with a high vacuum between the walls to reduce heat transfer into the liquid. Typical laboratory Dewar flasks are spherical, made of glass and protected in a metal outer container. Dewar flasks for extremely cold liquids such as liquid helium have another double-walled container filled with liquid nitrogen. Dewar flasks are named after their inventor, James Dewar, the man who first liquefied hydrogen. Thermos bottles are smaller vacuum flasks fitted in a protective casing. Cryogenic barcode labels are used to mark Dewar flasks containing these liquids, and will not frost over down to −195 degrees Celsius. Cryogenic transfer pumps are the pumps used on LNG piers to transfer liquefied natural gas from LNG carriers to LNG storage tanks, as are cryogenic valves.
==== Cleveland Settlement ==== The United States' three largest pharmaceutical distributors, AmerisourceBergen, Cardinal Health and McKesson Corporation reached an agreement in October 2019 where they will pay two Ohio counties a combined US$215 million. As part of the deal, Israel drug manufacturer Teva will also provide US$20 million in cash and US$25 million worth of Suboxone, an opioid addiction treatment. Cuyahoga County (Cleveland) and Summit County (Akron) brought the suit in US Federal District Court (Northern District of Ohio). The settlement averted what would have been the first federal trial over the US opioid crisis. The defendants offered no admission of wrongdoing. More than 2,600 lawsuits against the US pharmaceutical industry are still in the offing. The plaintiffs in those cases said the Ohio settlement allows them time to attempt to negotiate a national settlement. It also pressures the participants to work out a deal, as every partial settlement diminishes the aggregate total the companies will be able to pay. The two counties had reached a similar settlement of US$20.4 million with Johnson & Johnson and its subsidiary Ethicon, Inc. earlier in October 2019.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.